Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials

M.V. Maraldo; F. Giusti; I.R. Vogelius; M. Lundemann; M.A.E. van der Kaaij; S. Ramadan; B. Meulemans; M. Henry-Amar; B.M.P. Aleman; J. Raemaekers; P. Meijnders; E.C. Moser; H.C. Kluin-Nelemans; P. Feugier; O Casasnovas; C. Fortpied; L. Specht

doi:10.1016/S2352-3026(15)00153-2

Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials

M.V. Maraldo, F. Giusti, I.R. Vogelius, M. Lundemann, M.A.E. van der Kaaij, S. Ramadan, B. Meulemans, M. Henry-Amar, B.M.P. Aleman, J. Raemaekers, P. Meijnders, E.C. Moser, H.C. Kluin-Nelemans, P. Feugier, O Casasnovas, C. Fortpied, L. Specht

Internal medicine

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	E492-E502
Journal	Lancet haematology
Volume	2
Issue number	11
DOIs	https://doi.org/10.1016/S2352-3026(15)00153-2
Publication status	Published - 2015

Access to Document

10.1016/S2352-3026(15)00153-2

Cite this

Maraldo, M. V., Giusti, F., Vogelius, I. R., Lundemann, M., van der Kaaij, M. A. E., Ramadan, S., ... Specht, L. (2015). Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet haematology, 2(11), E492-E502. https://doi.org/10.1016/S2352-3026(15)00153-2

Maraldo, M.V. ; Giusti, F. ; Vogelius, I.R. ; Lundemann, M. ; van der Kaaij, M.A.E. ; Ramadan, S. ; Meulemans, B. ; Henry-Amar, M. ; Aleman, B.M.P. ; Raemaekers, J. ; Meijnders, P. ; Moser, E.C. ; Kluin-Nelemans, H.C. ; Feugier, P. ; Casasnovas, O ; Fortpied, C. ; Specht, L. / Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. In: Lancet haematology. 2015 ; Vol. 2, No. 11. pp. E492-E502.

@article{419fd3a4138c4e6ea7fb83f81c8d4141,

title = "Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials",

author = "M.V. Maraldo and F. Giusti and I.R. Vogelius and M. Lundemann and {van der Kaaij}, M.A.E. and S. Ramadan and B. Meulemans and M. Henry-Amar and B.M.P. Aleman and J. Raemaekers and P. Meijnders and E.C. Moser and H.C. Kluin-Nelemans and P. Feugier and O Casasnovas and C. Fortpied and L. Specht",

year = "2015",

doi = "10.1016/S2352-3026(15)00153-2",

language = "Undefined/Unknown",

volume = "2",

pages = "E492--E502",

journal = "Lancet haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "11",

}

Maraldo, MV, Giusti, F, Vogelius, IR, Lundemann, M, van der Kaaij, MAE, Ramadan, S, Meulemans, B, Henry-Amar, M, Aleman, BMP, Raemaekers, J, Meijnders, P, Moser, EC, Kluin-Nelemans, HC, Feugier, P, Casasnovas, O, Fortpied, C & Specht, L 2015, 'Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials', Lancet haematology, vol. 2, no. 11, pp. E492-E502. https://doi.org/10.1016/S2352-3026(15)00153-2

Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. / Maraldo, M.V.; Giusti, F.; Vogelius, I.R.; Lundemann, M.; van der Kaaij, M.A.E.; Ramadan, S.; Meulemans, B.; Henry-Amar, M.; Aleman, B.M.P.; Raemaekers, J.; Meijnders, P.; Moser, E.C.; Kluin-Nelemans, H.C.; Feugier, P.; Casasnovas, O; Fortpied, C.; Specht, L.

In: Lancet haematology, Vol. 2, No. 11, 2015, p. E492-E502.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials

AU - Maraldo, M.V.

AU - Giusti, F.

AU - Vogelius, I.R.

AU - Lundemann, M.

AU - van der Kaaij, M.A.E.

AU - Ramadan, S.

AU - Meulemans, B.

AU - Henry-Amar, M.

AU - Aleman, B.M.P.

AU - Raemaekers, J.

AU - Meijnders, P.

AU - Moser, E.C.

AU - Kluin-Nelemans, H.C.

AU - Feugier, P.

AU - Casasnovas, O

AU - Fortpied, C.

AU - Specht, L.

PY - 2015

Y1 - 2015

U2 - 10.1016/S2352-3026(15)00153-2

DO - 10.1016/S2352-3026(15)00153-2

M3 - Article

VL - 2

SP - E492-E502

JO - Lancet haematology

JF - Lancet haematology

SN - 2352-3026

IS - 11

ER -